{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T07:13:17Z","timestamp":1775286797644,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T00:00:00Z","timestamp":1609632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T00:00:00Z","timestamp":1609632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001111","name":"Cancer Australia","doi-asserted-by":"publisher","award":["1129568"],"award-info":[{"award-number":["1129568"]}],"id":[{"id":"10.13039\/501100001111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1135285"],"award-info":[{"award-number":["1135285"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1150989"],"award-info":[{"award-number":["1150989"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"publisher","award":["Robinson Fellowship"],"award-info":[{"award-number":["Robinson Fellowship"]}],"id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1245\/s10434-020-09270-3","type":"journal-article","created":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T20:02:51Z","timestamp":1609704171000},"page":"4561-4569","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Performance of Long-Term CT and PET\/CT Surveillance for Detection of Distant Recurrence in Patients with Resected Stage IIIA\u2013D Melanoma"],"prefix":"10.1245","volume":"28","author":[{"given":"Robin M.","family":"Turner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mbathio","family":"Dieng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikita","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaxu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda A. G.","family":"Nijhuis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omgo E.","family":"Nieweg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Einstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Emmett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah J.","family":"Lord","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander M.","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robyn P. M.","family":"Saw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachael L.","family":"Morton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,3]]},"reference":[{"key":"9270_CR1","unstructured":"National Cancer Control Indicators. Cancer Mortality, Cancer Australia; 2018"},{"key":"9270_CR2","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1200\/JCO.2009.26.2063","volume":"28","author":"E Romano","year":"2010","unstructured":"Romano E, Scordo M, Dusza SW, et al. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol. 2010;28:3042\u20137","journal-title":"J Clin Oncol."},{"key":"9270_CR3","doi-asserted-by":"crossref","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:472\u2013492","DOI":"10.3322\/caac.21409"},{"key":"9270_CR4","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1097\/CMR.0b013e3283480256","volume":"21","author":"RA Abbott","year":"2011","unstructured":"Abbott RA, Acland KM, Harries M, et al. The role of positron emission tomography with computed tomography in the follow-up of asymptomatic cutaneous malignant melanoma patients with a high risk of disease recurrence. Melanoma Research. 2011;21:446\u2013449","journal-title":"Melanoma Research."},{"key":"9270_CR5","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1245\/s10434-017-5768-8","volume":"24","author":"TS Park","year":"2017","unstructured":"Park TS, Phan GQ, Yang JC, et al. Routine Computer Tomography Imaging for the Detection of Recurrences in High-Risk Melanoma Patients. Ann Surg Oncol. 2017;24:947\u2013951","journal-title":"Ann Surg Oncol."},{"key":"9270_CR6","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.amjsurg.2013.04.012","volume":"207","author":"JJ Baker","year":"2014","unstructured":"Baker JJ, Meyers MO, Frank J, et al. Routine restaging PET\/CT and detection of initial recurrence in sentinel lymph node positive stage III melanoma. Am J Surg. 2014;207:549\u201354","journal-title":"Am J Surg."},{"key":"9270_CR7","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/CMR.0000000000000344","volume":"27","author":"RA Leon-Ferre","year":"2017","unstructured":"Leon-Ferre RA, Kottschade LA, Block MS, et al. Association between the use of surveillance PET\/CT and the detection of potentially salvageable occult recurrences among patients with resected high-risk melanoma. Melanoma Research. 2017;27:335\u2013341","journal-title":"Melanoma Research."},{"key":"9270_CR8","unstructured":"Barbour A, Guminski A, Liu W, Menzies S, Morton R; Cancer Council Australia Melanoma Guidelines Working Party. What is the ideal setting, duration and frequency of follow-up for melanoma patients? Cancer Council Australia Melanoma Guidelines Working Party. Clinical practice guidelines for the diagnosis and management of melanoma."},{"key":"9270_CR9","unstructured":"National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology (NCCN Guidelines): Cutaneous Melanoma. National Comprehensive Cancer Network; 2019"},{"key":"9270_CR10","volume-title":"Clinical Practice Guidelines in Oncology","author":"National Comprehensive Cancer Network","year":"2016","unstructured":"National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Melanoma. National Comprehensive Cancer Network; 2016"},{"key":"9270_CR11","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1200\/JCO.18.01219","volume":"36","author":"A Hauschild","year":"2018","unstructured":"Hauschild A, Dummer R, Schadendorf D, et al. Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma. J Clin Oncol. 2018;36:3441\u20133449","journal-title":"J Clin Oncol."},{"key":"9270_CR12","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ejca.2019.05.020","volume":"116","author":"AMM Eggermont","year":"2019","unstructured":"Eggermont AMM, Blank CU, Mandala M, et al. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325\/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. Eur J Cancer. 2019;116:148\u2013157","journal-title":"Eur J Cancer."},{"key":"9270_CR13","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/jamaophthalmol.2013.564","volume":"131","author":"JC Wen","year":"2013","unstructured":"Wen JC, Sai V, Straatsma BR, et al. Radiation-Related Cancer Risk Associated With Surveillance Imaging for Metastasis From Choroidal Melanoma. JAMA Ophthalmology. 2013;131:56\u201361","journal-title":"JAMA Ophthalmology."},{"key":"9270_CR14","volume-title":"Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII Phase 2","author":"National Research Council","year":"2006","unstructured":"National Research Council. Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII Phase 2. Washington, DC: The National Academies Press; 2006"},{"key":"9270_CR15","doi-asserted-by":"publisher","first-page":"h6080","DOI":"10.1136\/bmj.h6080","volume":"352","author":"V Prasad","year":"2016","unstructured":"Prasad V, Lenzer J, Newman DH. Why cancer screening has never been shown to \u201csave lives\u201d\u2014and what we can do about it. BMJ. 2016;352:h6080","journal-title":"BMJ."},{"key":"9270_CR16","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1097\/SLA.0000000000000233","volume":"259","author":"NM Rueth","year":"2014","unstructured":"Rueth NM, Xing Y, Chiang YJ, et al. Is surveillance imaging effective for detecting surgically treatable recurrences in patients with melanoma? A comparative analysis of stage-specific surveillance strategies. Ann Surg. 2014;259:1215\u201322","journal-title":"Ann Surg."},{"key":"9270_CR17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.cllc.2016.03.007","volume":"17","author":"GX Wu","year":"2016","unstructured":"Wu GX, Raz DJ, Brown L, et al. Psychological Burden Associated With Lung Cancer Screening: A Systematic Review. Clin Lung Cancer. 2016;17:315\u2013324","journal-title":"Clin Lung Cancer."},{"key":"9270_CR18","doi-asserted-by":"publisher","first-page":"e0220148","DOI":"10.1371\/journal.pone.0220148","volume":"14","author":"L Li","year":"2019","unstructured":"Li L, Severens JL, Mandrik O. Disutility associated with cancer screening programs: A systematic review. PLoS One. 2019;14:e0220148","journal-title":"PLoS One."},{"key":"9270_CR19","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1378\/chest.111.6.1583","volume":"111","author":"SS Raab","year":"1997","unstructured":"Raab SS, Hornberger J. The effect of a patient\u2019s risk-taking attitude on the cost effectiveness of testing strategies in the evaluation of pulmonary lesions. Chest. 1997;111:1583\u201390","journal-title":"Chest."},{"key":"9270_CR20","doi-asserted-by":"publisher","first-page":"286","DOI":"10.4103\/1450-1147.215491","volume":"16","author":"P Chandra","year":"2017","unstructured":"Chandra P, Purandare N, Shah S, et al. Diagnostic Accuracy and Impact of Fluorodeoxyglucose Positron Emission Tomography\/Computed Tomography in Preoperative Staging of Cutaneous Malignant Melanoma: Results of a Prospective Study in Indian Population. World journal of nuclear medicine. 2017;16:286\u2013292","journal-title":"World journal of nuclear medicine."},{"key":"9270_CR21","first-page":"429","volume":"43","author":"P Royston","year":"1994","unstructured":"Royston P, Altman DG. Regression Using Fractional Polynomials of Continuous Covariates: Parsimonious Parametric Modelling. Journal of the Royal Statistical Society Series C (Applied Statistics). 1994;43:429\u2013467","journal-title":"Journal of the Royal Statistical Society Series C (Applied Statistics)."},{"key":"9270_CR22","first-page":"17","volume":"4","author":"M Danielsen","year":"2013","unstructured":"Danielsen M, Hojgaard L, Kjaer A, et al. Positron emission tomography in the follow-up of cutaneous malignant melanoma patients: a systematic review. Am J Nucl Med Mol Imaging. 2013;4:17\u201328","journal-title":"Am J Nucl Med Mol Imaging."},{"key":"9270_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.suronc.2014.01.002","volume":"23","author":"AM Rodriguez Rivera","year":"2014","unstructured":"Rodriguez Rivera AM, Alabbas H, Ramjaun A, et al. Value of positron emission tomography scan in stage III cutaneous melanoma: a systematic review and meta-analysis. Surg Oncol. 2014;23:11\u20136","journal-title":"Surg Oncol."},{"key":"9270_CR24","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1080\/0284186X.2016.1213879","volume":"55","author":"I Koskivuo","year":"2016","unstructured":"Koskivuo I, Kemppainen J, Giordano S, et al. Whole body PET\/CT in the follow-up of asymptomatic patients with stage IIB-IIIB cutaneous melanoma. Acta Oncol. 2016;55:1355\u20131359","journal-title":"Acta Oncol."},{"key":"9270_CR25","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/jnci\/djq455","volume":"103","author":"Y Xing","year":"2011","unstructured":"Xing Y, Bronstein Y, Ross MI, et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst. 2011;103:129\u201342","journal-title":"J Natl Cancer Inst."},{"key":"9270_CR26","doi-asserted-by":"publisher","first-page":"941921","DOI":"10.1155\/2012\/941921","volume":"2012","author":"Y Xing","year":"2012","unstructured":"Xing Y, Cromwell KD, Cormier JN. Review of diagnostic imaging modalities for the surveillance of melanoma patients. Dermatol Res Pract. 2012;2012:941921","journal-title":"Dermatol Res Pract."},{"key":"9270_CR27","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1245\/s10434-019-07311-0","volume":"26","author":"AAG Nijhuis","year":"2019","unstructured":"Nijhuis AAG, Dieng M, Khanna N, et al. False-Positive Results and Incidental Findings with Annual CT or PET\/CT Surveillance in Asymptomatic Patients with Resected Stage III Melanoma. Annals of Surgical Oncology. 2019;26:1860\u20131868","journal-title":"Annals of Surgical Oncology."},{"key":"9270_CR28","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/MNM.0b013e3280708ecf","volume":"28","author":"MS Falk","year":"2007","unstructured":"Falk MS, Truitt AK, Coakley FV, et al. Interpretation, accuracy and management implications of FDG PET\/CT in cutaneous malignant melanoma. Nucl Med Commun. 2007;28:273\u201380","journal-title":"Nucl Med Commun."},{"key":"9270_CR29","first-page":"1215","volume":"259","author":"NM Rueth","year":"2014","unstructured":"Rueth NM, Xing Y, Chiang Y-J, et al. Is Surveillance Imaging Effective for Detecting Surgically Treatable Recurrences in Patients With Melanoma? A Comparative Analysis of Stage-Specific Surveillance Strategies. 2014;259:1215\u20131222","journal-title":"A Comparative Analysis of Stage-Specific Surveillance Strategies."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-09270-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-020-09270-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-09270-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T16:10:06Z","timestamp":1625242206000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-020-09270-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,3]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["9270"],"URL":"https:\/\/doi.org\/10.1245\/s10434-020-09270-3","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,3]]},"assertion":[{"value":"9 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"John F. Thompson has received honoraria for advisory board participation from BMS Australia, MSD Australia, GSK and Provectus Inc., and travel support from GSK and Provectus Inc. Robyn P.M. Saw has received honoraria for advisory board participation from MSD Australia and Novartis, and speaking honoraria from BMS Australia. Alexander M. Menzies has received honoraia for advisory board participation from BMS, MSD, Novartis, Roche, and Pierre-Fabre, and QBiotics. Robin M. Turner, Mbathio Dieng, Nikita Khanna, Mai Nguyen, Jiaxu Zeng, Amanda A.G. Nijhuis, Omgo E. Nieweg, Andrew J. Einstein, Louise Emmett, Sarah J. Lord, and Rachael L. Morton have no disclosures to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}